Evidence map›Paper›PMID 38104992›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Remission of Cardiac Sarcoidosis after the Administration of Methotrexate as First-line Drug Therapy.

Hirochika Yamasaki, Hidekazu Kondo, Naoko Ogawa, Kazuki Mitarai, Yumi Ishi, Shotaro Saito, Naohiko Takahashi

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hirochika YamasakiDepartment of Cardiology and Clinical Examination, Faculty of Medicine, Oita University, Japan.
Hidekazu KondoDepartment of Cardiology and Clinical Examination, Faculty of Medicine, Oita University, Japan.
Naoko OgawaDepartment of Cardiology and Clinical Examination, Faculty of Medicine, Oita University, Japan.
Kazuki MitaraiDepartment of Cardiology and Clinical Examination, Faculty of Medicine, Oita University, Japan.
Yumi IshiDepartment of Cardiology and Clinical Examination, Faculty of Medicine, Oita University, Japan.
Shotaro SaitoDepartment of Cardiology and Clinical Examination, Faculty of Medicine, Oita University, Japan.
Naohiko TakahashiDepartment of Cardiology and Clinical Examination, Faculty of Medicine, Oita University, Japan.
Oita University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 54-year-old woman developed new-onset heart failure and was diagnosed with cardiac sarcoidosis. An implantable cardioverter-defibrillator with biventricular pacing was implanted before immunosuppressive therapy to prevent sudden death. The patient refused oral steroids because she disliked their specific side effects and potential adverse events with long-term use; therefore, methotrexate was chosen as an alternative first-line drug. Nine months after starting oral therapy,

Indexed as

CardiomyopathiesMethotrexateRemission InductionSarcoidosisFemaleHeart FailureHumansImmunosuppressive AgentsMiddle AgedPositron-Emission TomographyTreatment OutcomeImmunosuppressive AgentsMethotrexate18F-fluorodeoxyglucose positron emission tomographycardiac sarcoidosiscorticosteroidsmethotrexate

Identifiers

PMID38104992
PMCPMC11358737
OpenAlexW4389855061

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.